Phase 1 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have advanced breast cancer (either spread to other parts of the body, or returned in the local area) that cannot be cured.
- Your tumor has been tested and shows specific genetic changes in certain genes called PIK3CA, AKT1, or PTEN.
- You have previously received at least one hormone-based (endocrine) therapy for your advanced or metastatic breast cancer, OR your cancer came back or got worse during or within 12 months of finishing hormone therapy after your initial treatment.
- Your cancer got worse while you were taking a specific type of treatment called a CDK4/6 inhibitor (such as palbociclib, ribociclib, or abemaciclib) combined with a hormone therapy called fulvestrant or an aromatase inhibitor.
Who may not be able to join:
- You have cancer that has recently spread to your brain or spinal cord, or this is an active, ongoing problem.
- Your cancer has spread widely to internal organs and is causing serious, potentially life-threatening symptoms in the near term — for example, large uncontrolled fluid build-up in the abdomen, lungs, or around the heart, cancer spreading through the lymph vessels in the lungs, or more than half of your liver being affected.
- You still have significant side effects from previous radiation treatment that have not improved to a mild level, with the exception of hair loss or mild-to-moderate nerve-related symptoms such as tingling or numbness (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-332-7961
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants Experiencing Dose-limiting Toxicity When Administered MEN2312; Recommended Phase 2 Dose (RP2D) of MEN2312
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.